S&P 500   2,938.02 (-1.37%)
DOW   25,268.73 (-1.93%)
QQQ   204.33 (-0.64%)
MSFT   161.03 (+1.80%)
NVDA   263.09 (+4.15%)
BABA   203.23 (-0.88%)
MU   51.58 (+1.98%)
GE   10.42 (+0.29%)
TSLA   647.82 (-4.59%)
T   35.09 (-1.79%)
ACB   1.35 (-6.90%)
F   6.87 (-1.43%)
NFLX   363.65 (-2.17%)
BAC   28.43 (-2.40%)
GILD   68.25 (-6.07%)
DIS   116.93 (-0.95%)
S&P 500   2,938.02 (-1.37%)
DOW   25,268.73 (-1.93%)
QQQ   204.33 (-0.64%)
MSFT   161.03 (+1.80%)
NVDA   263.09 (+4.15%)
BABA   203.23 (-0.88%)
MU   51.58 (+1.98%)
GE   10.42 (+0.29%)
TSLA   647.82 (-4.59%)
T   35.09 (-1.79%)
ACB   1.35 (-6.90%)
F   6.87 (-1.43%)
NFLX   363.65 (-2.17%)
BAC   28.43 (-2.40%)
GILD   68.25 (-6.07%)
DIS   116.93 (-0.95%)
S&P 500   2,938.02 (-1.37%)
DOW   25,268.73 (-1.93%)
QQQ   204.33 (-0.64%)
MSFT   161.03 (+1.80%)
NVDA   263.09 (+4.15%)
BABA   203.23 (-0.88%)
MU   51.58 (+1.98%)
GE   10.42 (+0.29%)
TSLA   647.82 (-4.59%)
T   35.09 (-1.79%)
ACB   1.35 (-6.90%)
F   6.87 (-1.43%)
NFLX   363.65 (-2.17%)
BAC   28.43 (-2.40%)
GILD   68.25 (-6.07%)
DIS   116.93 (-0.95%)
S&P 500   2,938.02 (-1.37%)
DOW   25,268.73 (-1.93%)
QQQ   204.33 (-0.64%)
MSFT   161.03 (+1.80%)
NVDA   263.09 (+4.15%)
BABA   203.23 (-0.88%)
MU   51.58 (+1.98%)
GE   10.42 (+0.29%)
TSLA   647.82 (-4.59%)
T   35.09 (-1.79%)
ACB   1.35 (-6.90%)
F   6.87 (-1.43%)
NFLX   363.65 (-2.17%)
BAC   28.43 (-2.40%)
GILD   68.25 (-6.07%)
DIS   116.93 (-0.95%)
Log in

NASDAQ:OBLN - Obalon Therapeutics Stock Price, Forecast & News

$1.43
+0.07 (+5.15 %)
(As of 02/28/2020 01:24 PM ET)
Today's Range
$1.07
Now: $1.43
$1.43
50-Day Range
$1.36
MA: $1.83
$2.02
52-Week Range
$1.35
Now: $1.43
$19.40
Volume27,308 shs
Average Volume233,029 shs
Market Capitalization$11.05 million
P/E RatioN/A
Dividend YieldN/A
Beta-4.63
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
CUSIPN/A
Phone844-362-2566

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.10 million
Book Value$5.57 per share

Profitability

Net Income$-37,380,000.00
Net Margins-607.48%

Miscellaneous

Employees100
Market Cap$11.05 million
Next Earnings Date5/8/2020 (Estimated)
OptionableOptionable

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.


Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics shares reverse split before market open on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) released its quarterly earnings data on Thursday, February, 27th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.06. The business earned $0.79 million during the quarter. Obalon Therapeutics had a negative return on equity of 228.96% and a negative net margin of 607.48%. View Obalon Therapeutics' Earnings History.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, May 8th 2020. View Earnings Estimates for Obalon Therapeutics.

What price target have analysts set for OBLN?

2 brokerages have issued 12-month price objectives for Obalon Therapeutics' stock. Their forecasts range from $10.00 to $15.00. On average, they expect Obalon Therapeutics' stock price to reach $12.50 in the next year. This suggests a possible upside of 839.8% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

What is the consensus analysts' recommendation for Obalon Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.

Has Obalon Therapeutics been receiving favorable news coverage?

News coverage about OBLN stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obalon Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Obalon Therapeutics.

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:
  • Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
  • Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 57)
  • Ms. Daina Schmidt, VP of Marketing

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

Who are Obalon Therapeutics' major shareholders?

Obalon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Oxford Asset Management LLP (0.55%). Company insiders that own Obalon Therapeutics stock include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Institutional Ownership Trends for Obalon Therapeutics.

Which major investors are buying Obalon Therapeutics stock?

OBLN stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP. Company insiders that have bought Obalon Therapeutics stock in the last two years include Amy Vandenberg, Interwest Partners X Lp, Kim P Kamdar, Neil Drake, Nooshin Hussainy, Parters Vii L P Domain and William J Plovanic. View Insider Buying and Selling for Obalon Therapeutics.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $1.33.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $10.28 million and generates $9.10 million in revenue each year. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is http://www.obalon.com/.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  493
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel